# Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

Study · id `cardio:ct-nct01976507` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01976507](<https://clinicaltrials.gov/study/NCT01976507>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01976507

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT01976507. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2016-12 (actual). Results posted on 2017-09-12.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT01976507, source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)
- Started: 2013-10 (actual) (ClinicalTrials.gov record NCT01976507, source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT01976507, source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT01976507, source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)
- Results first posted: 2017-09-12 (ClinicalTrials.gov record NCT01976507, source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01976507, source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01976507-2017-09-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
- Condition: Atrial Fibrillation
- Condition: Atrial Flutter
- Intervention (Drug): dabigatran etexilate mesylate
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Atrial flutter (`cardio:atrial-flutter`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 3eaf9f6b916f9c9d822e3334831ec10f9d5be58c03c7681983f75aa4abed2bf7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
